Literature DB >> 27974096

Positive correlation between inflammation on sacroiliac joint MRI and serum C-terminal telopeptide of type-I collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis.

Kwi Young Kang1, Joon-Yong Jung2, Yeon Sik Hong1, Ji Hyeon Ju3, Sung-Hwan Park4.   

Abstract

OBJECTIVES: To identify the clinical disease activity scores and laboratory markers that best reflect magnetic resonance imaging (MRI)-determined sacroiliac joint (SIJ) inflammation in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
METHODS: This cross-sectional study included all consecutive patients who presented with axial spondyloarthritis in 2013-2015. All underwent SIJ MRI. The bone marrow oedema in the inflammatory lesions on MRI was scored using the SPondyloArthritis Research Consortium of Canada (SPARCC) method. Bone-specific alkaline phosphatase (BALP), serum C-terminal telopeptide of type-I collagen (sCTX-I), and inflammatory markers were measured. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) were assessed. The correlations between the MRI-determined SIJ inflammation scores and disease activity scores and laboratory variables were evaluated.
RESULTS: Of the 81 patients with axSpA, 45 had AS and 36 had nr-axSpA. The AS and nr-axSpA groups did not differ in terms of disease activity scores, physical functional index, or MRI-determined SIJ inflammation. Erythrocyte sedimentation rate, C-reactive protein, and ASDAS correlated with MRI inflammatory scores in nr-axSpA but not in AS. sCTX-I correlated with MRI-determined SIJ inflammatory scores in AS only. BASDAI and BALP levels did not associate with MRI inflammatory scores in either group. Multivariate analysis showed that sCTX-I associated independently with MRI inflammatory score in AS (β=17.047, p=0.038).
CONCLUSIONS: Inflammatory markers and ASDAS correlated with active sacroiliitis on MRI in nr-axSpA only. In AS, only sCTX-I correlated with active inflammation on SIJ MRI. sCTX-I may be useful as a marker of objective inflammation in AS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27974096

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

Review 1.  Biomarkers in axial spondyloarthritis and low back pain: a comprehensive review.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2021-10-21       Impact factor: 2.980

Review 2.  Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.

Authors:  James Cheng-Chung Wei; Chin-Hsiu Liu; Jui-Cheng Tseng; Lin-Fen Hsieh; Chun-Hsiung Chen; Hsin-Hua Chen; Hung-An Chen; Ying-Chou Chen; Chung-Tei Chou; Hsien-Tzung Liao; Yi-Chun Lin; Shue-Fen Luo; Deng-Ho Yang; Kai-Jieh Yeo; Wen-Chan Tsai
Journal:  Int J Rheum Dis       Date:  2019-11-27       Impact factor: 2.454

3.  Trends in fractures in patients with spondyloarthritis: a nationwide population-based study (TREND-EspA study).

Authors:  Ramon Mazzucchelli; Raquel Almodovar; Elisa Dieguez-Costa; Natalia Crespi Villarias; Elia Pérez-Fernandez; Alberto García-Vadillo
Journal:  Osteoporos Int       Date:  2021-08-02       Impact factor: 4.507

4.  Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.

Authors:  Walter P Maksymowych; Désirée van der Heijde; Xenofon Baraliakos; Atul Deodhar; Sarah P Sherlock; David Li; Dona Fleishaker; Thijs Hendrikx; Keith S Kanik
Journal:  Rheumatology (Oxford)       Date:  2018-08-01       Impact factor: 7.580

5.  Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis.

Authors:  Markéta Hušáková; Anne-C Bay-Jensen; Šárka Forejtová; Kateřina Zegzulková; Michal Tomčík; Monika Gregová; Kristýna Bubová; Jana Hořínková; Jindra Gatterová; Karel Pavelka; Anne Sofie Siebuhr
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.